In this study, we report a second monogenic form of ALS linked to altered sphingolipid metabolism with six patients from independent families with a recurrent, de novo, dominantly acting, monoallelic pathogenic variant in SPTLC2, manifesting with severe juvenile ALS with rapid progression. Here, SPTLC2 is linked to amyotrophic lateral sclerosis.